Using the PHQ-9 and GAD-7 as Feedback Instruments in Brief Psychotherapy

Depressive Symptoms Clinical Trial

Official title:

Using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7-Item Scale (GAD-7) as Feedback Instruments in Brief Psychotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02656641
• Other study ID #: 35156
• Status: Completed
• Phase: N/A
• First received: November 25, 2015
• Last updated: July 18, 2017
• Start date: November 2015
• Est. completion date: August 31, 2016

Study information

• Verified date: July 2017
• Source: Christiana Care Health Services
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the effects of client feedback, using the Patient Health Questionnaire - 9 and Generalized Anxiety Disorder 7-Item Scale, on depression and anxiety in individuals undergoing brief psychotherapy. Client feedback allows therapists to monitor treatment progress in real time. Identifying an easily accessible treatment intervention, which utilizes commonly used scales, that potentially enhances the effect of brief psychotherapy and improves treatment outcomes is a valuable endeavor with clear implications for therapy practices. It is hypothesized that clients who complete these scales each session will show greater symptom improvement than clients who do not complete the scales.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: August 31, 2016
• Est. primary completion date: August 31, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Diagnosis of Major Depressive Disorder, Generalized Anxiety Disorder, or Adjustment Disorder

Exclusion Criteria:

• Require a higher level of care than brief psychotherapy, or have been diagnosed with an intellectual disability, personality disorder, substance use disorder, or major medical illness

Related Conditions & MeSH terms

• Anxiety Disorders
• Anxiety States, Neurotic
• Depression
• Depressive Symptoms

Intervention

Behavioral:
• Continuous Client Feedback
Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
• Continuous Self Feedback
Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.

Locations

Country	Name	City	State
United States	Christiana Care Health System - Adult Bridge Program	Wilmington	Delaware

Sponsors (2)

Lead Sponsor	Collaborator
Christiana Care Health Services	Immaculata University

Country where clinical trial is conducted

United States, 

References & Publications (3)

Blais MA, Lenderking WR, Baer L, deLorell A, Peets K, Leahy L, Burns C. Development and initial validation of a brief mental health outcome measure. J Pers Assess. 1999 Dec;73(3):359-73. — View Citation

Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. — View Citation

Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999 Nov 10;282(18):1737-44. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in depressive symptoms as assessed by Patient Health Questionnaire-9	Assesses depressive symptoms	Baseline and end of treatment up to 10 weeks
Primary	Change in anxiety symptoms as assessed by Generalized Anxiety Disorder 7-Item Scale	Assesses anxiety symptoms	Baseline and end of treatment up to 10 weeks
Secondary	World Health Organization - Quality of Life BREF Scale	Assesses domains of physical health, psychological health, social relationships, and environment	Baseline and end of treatment up to 10 weeks
Secondary	Schwartz Outcome Scale	Monitors treatment outcomes	Baseline and end of treatment up to 10 weeks

External Links

•   World Health Organization - Quality of Life BREF Scale, pg 100-102